← Evidence map

ArticleAmerican journal of hematology2026

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

Maximilian J Steinhardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis. | OpenQuestion